Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLTE Belite Bio, Inc.

Post-Mkt 10-15 17:52:05 EDT

152.62

-0.10

-0.07%

盘后152.60

-0.02-0.01%

16:43 EDT

High155.47	Low152.13	Vol195.86K
Open153.87	D1 Closing152.72	Amplitude2.19%
Mkt Cap6.15B	Tradable Cap2.98B	Total Shares40.27M
T/O30.20M	T/O Rate1.00%	Tradable Shares19.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":152.62,"timestamp":1792094400000,"preClose":152.72,"halted":0,"volume":195857,"hourTrading":{"tag":"盘后","latestPrice":152.6,"preClose":152.62,"latestTime":"16:43 EDT","volume":3177,"amount":484873.74,"timestamp":1792096985416,"change":-0.02,"changeRate":-0.000131,"amplitude":0.000131},"delay":0,"changeRate":-0.0006547930853849811,"floatShares":19550700,"shares":40272144,"eps":-2.738223,"marketStatus":"Post-Mkt","change":-0.1,"latestTime":"10-15 17:52:05 EDT","open":153.87,"high":155.47,"low":152.13,"amount":30203151.058539998,"amplitude":0.02187,"askPrice":155.6,"askSize":12,"bidPrice":150,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.738223,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1792108800000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":152.72,"preHourTrading":{"tag":"盘前","latestPrice":153.1,"preClose":152.72,"latestTime":"07:09 EDT","volume":137,"amount":20864.14922,"timestamp":1792062541671,"change":0.38,"changeRate":0.002488,"amplitude":0.026061},"postHourTrading":{"tag":"盘后","latestPrice":152.6,"preClose":152.62,"latestTime":"16:43 EDT","volume":3177,"amount":484873.74,"timestamp":1792096985416,"change":-0.02,"changeRate":-0.000131,"amplitude":0.000131},"volumeRatio":0.994456},"requestUrl":"/m/hq/s/BLTE/wiki","defaultTab":"wiki","newsList":[{"id":"2675058162","title":"Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675058162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675058162?lang=en_us&edition=fundamental","pubTime":"2026-10-15 19:40","pubTimestamp":1792064416,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-vertex-pharmaceuticals-vrtx-and-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-vertex-pharmaceuticals-vrtx-and-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APIE","IDNA","LU1674673691.USD","LU2236285917.USD","BIB","LU1069344957.HKD","PBE","FBT","IBB","XBI","IE00B2B36J28.USD","HCSG","GNMX","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0320765992.SGD","SAPH","XLV","AADR","LU0289739699.SGD","LU0823416689.USD","TBXU","CVY","IE00BJJMRZ35.SGD","VRTX","BK4588","SG9999001176.SGD","VERX","BK4533","LU1093756168.USD","DINT","LABU","BK4023","BBH","IE0002270589.USD","BK4137","LU0058720904.USD","LU2362541273.HKD","LU0757428866.USD","IBBQ","SG9999001176.USD","LU1035775433.USD","BLTE","ARMH","CORT","BK4567","DIVL","PSCH","LU0432979614.USD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675228783","title":"Belite Bio Seeks Tinlarebant Approval in Singapore, UK and Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2675228783","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675228783?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:01","pubTimestamp":1792008095,"startTime":"0","endTime":"0","summary":"Belite Bio Seeks Tinlarebant Approval in Singapore, UK and SwitzerlandBelite Bio filed marketing applications for tinlarebant to treat Stargardt disease type 1 in Singapore, the UK and Switzerland thr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nNDL2HD55G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4112","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","SG9999014005.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","BK4007","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","IE00BN0W2W23.USD","BK4585","LU0314104364.USD","SG9999014039.USD","LU2210149790.SGD","BCDF","LU2210150020.SGD","IE00BQXX3F31.USD","NDAQ","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675830322","title":"Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2675830322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675830322?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:00","pubTimestamp":1792008000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nTUA1CLHCM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675322837","title":"Belite Bio - U.S. Nda for Tinlarebant Accepted with Pdufa Target Action Date February 12, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2675322837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675322837?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:00","pubTimestamp":1792008000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nTUA1CLHCM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675322831","title":"Belite Bio - Submits Marketing Authorization Applications for Tinlarebant in Singapore, UK, and Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2675322831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675322831?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:00","pubTimestamp":1792008000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nTUA1CLHCM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673269087","title":"Belite Bio Chief Medical Officer Hendrik Peter Scholl Reports ADS Disposal Valued at $80,048.70","url":"https://stock-news.laohu8.com/highlight/detail?id=2673269087","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673269087?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:28","pubTimestamp":1791242901,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Medical Officer Hendrik Peter Scholl reports ADS disposal valued at $80,048.70Belite Bio Chief Medical Officer Hendrik Peter Scholl reported selling 500 American depositary shares on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL5VxsjL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Belite Bio Chief Medical Officer Hendrik Peter Scholl Reports ADS Disposal Valued at $80,048.70","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672662763","title":"Belite Bio (BLTE) Draws Fresh Valuation Attention After FDA Priority Review And Euretina Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2672662763","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672662763?lang=en_us&edition=fundamental","pubTime":"2026-10-01 22:19","pubTimestamp":1790864395,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) is drawing fresh attention after confirming multiple presentations at the Euretina Innovation Spotlight and main Euretina meeting in Vienna, alongside FDA priority review for its Tinlarebant new drug application.\nRecent excitement around Belite Bio has come alongside firm price momentum, with a 30-day share price return of 9.06% and a 90-day gain of 15.82%, while the 1-year total shareholder return of 131.05% and very large 3-year total shareholder return of about 5x...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-draws-fresh-valuation-attention-after-fda-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-draws-fresh-valuation-attention-after-fda-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BLTE","LABU","BK4588","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754772","title":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754772","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754772?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:00","pubTimestamp":1790856000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372849/0/en/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671770265","title":"Belite Bio to Present Phase 3 Dragon Topline Results for Tinlarebant in Adolescent Stargardt Disease at Euretina","url":"https://stock-news.laohu8.com/highlight/detail?id=2671770265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671770265?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640022,"startTime":"0","endTime":"0","summary":"Belite Bio to present Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease at EuretinaBelite Bio scheduled oral presentations at Euretina meetings in Vienna, including Phase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDLDLdYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BQXX3D17.EUR","LU0314104364.USD","BLTE","SG9999014021.USD","IE00BN0W2V16.EUR","BCDF","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00BQXX3F31.USD","SG9999014013.SGD","NDAQ","SG9999014005.SGD","BK4112","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014039.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4007","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755328","title":"Belite Bio CFO Chuang Hao-Yuan Sells USD 8.85 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755328","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755328?lang=en_us&edition=fundamental","pubTime":"2026-09-10 07:39","pubTimestamp":1788997165,"startTime":"0","endTime":"0","summary":"Belite Bio CFO Chuang Hao-Yuan sells USD 8.85 million in common sharesBelite Bio CFO Hao-Yuan Chuang sold 66,362 American depositary shares in transactions dated Sept. 4 and Sept. 8, 2026.Sales prices","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL6xW0C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CFO Chuang Hao-Yuan Sells USD 8.85 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666130587","title":"Mizuho Raises Price Target on Belite Bio to $234 From $220, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666130587","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666130587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:09","pubTimestamp":1788952179,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) has an average rating of buy and mean price target of $227.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666300172","title":"U.S. Research Roundup-Argan, Mastec, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2666300172","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666300172?lang=en_us&edition=fundamental","pubTime":"2026-09-09 14:55","pubTimestamp":1788936930,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Argan, Mastec, OracleSept 9 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Argan, Mastec and Oracle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4N4510GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRI","CRK","A","AEO","RTH","IBAT","CLH","EXP","STYL","CHYM","ANIP","FLNC","ANF","ARMK","CTEC","FSLR","DYN","ADBG","AVTR","BBOT","AGX","BRKR","DECK","AIRR","COLL","TXG","BBWI","DKS","ADBE","APD","BRZE","FRNW","ARKG","CC","FIGR","BLTE","CAI","AMRZ","CVS","CASY","AMRX","BETR","EVMN","SMOG","ABM","AKTS","TINY","ADBU","ASO","PLCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665379127","title":"Belite Bio Price Target Raised to $245.00/Share from $214.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665379127","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665379127?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:30","pubTimestamp":1788881400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665853373","title":"Belite Bio, Inc : H.c. Wainwright Raises Target Price to $245 from $214","url":"https://stock-news.laohu8.com/highlight/detail?id=2665853373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665853373?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:54","pubTimestamp":1788872092,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nAZN4TIZ3U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321016","title":"Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321016?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:05","pubTimestamp":1788861913,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) announced the submission of a New Drug Application to the Ministry of Health, Labour, and Welfare in Japan for tinlarebant in Sta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/belite-bio-submits-nda-to-mhlw-in-japan-for-tinlarebant-in-stgd1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/belite-bio-submits-nda-to-mhlw-in-japan-for-tinlarebant-in-stgd1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321865","title":"Belite Bio Files Japan NDA for Tinlarebant Under Sakigake Designation for Stargardt Disease Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321865?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861644,"startTime":"0","endTime":"0","summary":"Belite Bio files Japan NDA for tinlarebant under Sakigake designation for Stargardt disease type 1Belite Bio filed a Japan NDA with the MHLW for tinlarebant to treat Stargardt disease type 1 under the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4cKct7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BLTE","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","LU2210150020.SGD","SG9999014021.USD","BK4112","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4007","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BCDF","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014013.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329072","title":"Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan Under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329072?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA85NQCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329071","title":"Belite Bio, - FDA Accepts Nda with Priority Review for Tinlarebant; Pdufa Target Date Feb 12, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329071?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA85NQCS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369036","title":"Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665369036?lang=en_us&edition=fundamental","pubTime":"2026-09-06 13:05","pubTimestamp":1788671132,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Belite Bio, Inc. ADR on September 4 and set a price target of $220.00. The c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-belite-bio-inc-adr-blte-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-belite-bio-inc-adr-blte-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVY","BLTE","SAPH","AADR","DIVL","APIE","ARMH","DINT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665835938","title":"Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2665835938","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665835938?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:30","pubTimestamp":1788550247,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) shares rose 10% in Friday trading after Canaccord Genuity initiated coverage of the stock with a buy rating and a price target of $303.Intraday trading topped 510,150 shares, compared with the daily average of 188,179.Price: 188.98, Change: +17.89, Percent Change: +10.46","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com;belitebio.com","stockEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":-0.1172},{"period":"3month","weight":0.0136},{"period":"6month","weight":-0.0769},{"period":"1year","weight":0.9268},{"period":"ytd","weight":-0.0453}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0115},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.0837},{"period":"1year","weight":0.1621},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020711},{"month":2,"riseRate":0.75,"avgChangeRate":0.070972},{"month":3,"riseRate":0.25,"avgChangeRate":-0.067883},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011914},{"month":5,"riseRate":0.6,"avgChangeRate":0.032881},{"month":6,"riseRate":0.4,"avgChangeRate":0.163367},{"month":7,"riseRate":1,"avgChangeRate":0.188852},{"month":8,"riseRate":0.2,"avgChangeRate":0.073935},{"month":9,"riseRate":0.6,"avgChangeRate":0.03995},{"month":10,"riseRate":0.6,"avgChangeRate":0.159098},{"month":11,"riseRate":0.75,"avgChangeRate":0.12408},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction